By the end of this module, you will be able to:
✓ Compare the three meta-analyses conducted by the Cholesterol Treatment Trialists’ (CTT) Collaboration in 2008, 2010 and 2016
✓ Analyse the evidence underpinning the use of selective cholesterol-absorption inhibitors (i.e. ezetemibe), fibrates and PCSK9-inhibitors as lipid-lowering treatment for people with diabetes
✓ Identify lipid-lowering treatment options for people with diabetes across different age groups
This module includes self-marked assessments, such as knowledge checks and/or case studies, as well as a marked final assessment, which you can attempt up to five times. To complete the module, you must review all chapters, pass the final assessment (80% pass mark), and fill in our feedback form.